"10.1371_journal.pone.0083449","plos one","2014-01-08T00:00:00Z","Rigmor Thorstensson; Birger Trollfors; Nabil Al-Tawil; Maja Jahnmatz; Jakob Bergström; Margaretha Ljungman; Anna Törner; Lena Wehlin; Annie Van Broekhoven; Fons Bosman; Anne-Sophie Debrie; Nathalie Mielcarek; Camille Locht","Swedish Institute for Communicable Disease Control, Solna, Sweden; Karolinska Trial Alliance, Karolinska University Hospital, Stockholm, Sweden; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; Q-Biologicals, BioIncubator, Zwijnaarde, Belgium; Inserm, Lille, France; National Center for Scientific Research, Lille, France; Université Lille-Nord de France, Lille, France; Center for Infection and Immunity of Lille, Institut Pasteur de Lille, Lille, France","Conceived and designed the experiments: RT BT NAT MJ JB ML AT LW AVB FB ASD NM CL. Performed the experiments: RT BT NAT MJ ML AT LW. Analyzed the data: RT BT MJ ML LW AT JB CL. Contributed reagents/materials/analysis tools: AVB FB ASD. Wrote the paper: RT BT CL LW. Coordinating partner of the clinical trial in Sweden, responsible for the contacts with the sponsor and the authorities, lab manager at the Swedish Institute for Communicable Disease Control, author of the clinical study protocol, the clinical study report: RT. Safety officer and clinical manager on behalf of the Swedish Institute for Communicable Disease Control: BT. Principal Investigator of the trial and the Medical Director: NAT. Wrote statistical analysis plan: AT. Production and quality control of the vaccine according to Goood manufacturing Practice: AVB FB A-SD. Writing of technical documents for the preparation of the trial: NM.","Anne-Sophie Debrie, Camille Locht and Nathalie Mielcarek are inventors of patent applications on BPZE1 (Live attenuated Bordetella pertussis as a single dose vaccine against whooping cough, PCT/EP2007/001942, published under WO2007/104451; Vaccine for prophylaxis or treatment of an allergen-driven airway pathology, PCT/EP2010/055507, published under WO2010/12501; Influenza vaccine, composition and methods of use, PCT/IB2009/007153, published under WO2010/146414). None of them have currently been out-licensed for commercial purposes. Annie Van Broekhoven is employed by Q-Biologicals as CEO and has only a minor participation of 0.25% in the company. Fons Bosman is employed by Q-Biologicals. He has no participation in the company. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.","2014","01","Rigmor Thorstensson","RT",13,TRUE,13,7,8,4,TRUE,TRUE,FALSE,0,NA,FALSE
